SCHEMBL10074890

SCHEMBL10074890

CC(C)CNC(=O)c1ccc(O)c2nc3c(CO)c(O)c(-c4c(O)c(CO)c5nc6c(O)ccc(C(=O)NCC(C)C)c6nc5c4O)c(O)c3nc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.37
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
POLB P06746 1/20 0.37
TP53 P04637 1/20 0.37
MAOB P27338 1/20 0.35
HSD17B10 Q99714 2/20 0.35
GAA P10253 1/20 0.35
AKR1B10 O60218 1/20 0.34
AKR1B1 P15121 1/20 0.34
HTT P42858 2/20 0.34
TSHR P16473 1/20 0.34
CA2 P00918 1/20 0.33
ALDH1A1 P00352 3/20 0.33
HDAC4 P56524 1/20 0.33
ALOX12 P18054 1/20 0.33
PIM1 P11309 1/20 0.32
BAD Q92934 1/20 0.32
PIM2 Q9P1W9 1/20 0.32
RAB9A P51151 3/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16968741 0.91 MEN1 (0.34) SMN1; SMN2KMT2AMEN1POLBTP53
SCHEMBL10074406 0.87 NPC1 (0.46) SMN1; SMN2TP53RAB9ANPC1
SCHEMBL10074589 0.86 ALOX5 (0.39) KMT2AMEN1MAOBGAAAKR1B10
SCHEMBL10074892 0.84 EGFR (0.32) PIM1
SCHEMBL10074597 0.81 GSK3B (0.50) KMT2AGAAHTTHPGD
SCHEMBL16968745 0.81 BCL2 (0.45) SMN1; SMN2TP53RAB9ANPC1
SCHEMBL10075151 0.80 KDM4E (0.42) SMN1; SMN2KMT2AMEN1HSD17B10GAA
SCHEMBL20514733 0.79 SELL (0.39) KMT2AMEN1HTTALDH1A1ALOX12
SCHEMBL16968748 0.76
SCHEMBL10075152 0.70 KDM4E (0.38) KMT2AMEN1HSD17B10GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US claimed
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-9351971-B2 Substituted 2,2′-biphenazines for treating diseases EUTROPICS PHARMACEUTICALS, INC. (US) 2016-05-31 US disclosed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US disclosed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US disclosed
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS THERAPEUTICS, INC. 2015-08-06 US disclosed
US-8987271-B2 2,2′-biphenazine compounds and methods useful for treating disease EUTROPICS PHARMACEUTICALS, INC. (US) 2015-03-24 US disclosed
US-8987271-B2 2,2′-biphenazine compounds and methods useful for treating disease EUTROPICS PHARMACEUTICALS, INC. (US) 2015-03-24 US disclosed
US-8987271-B2 2,2′-biphenazine compounds and methods useful for treating disease EUTROPICS PHARMACEUTICALS, INC. (US) 2015-03-24 US disclosed
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-09-06 US disclosed
WO-2012088438-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES EUTROPICS PHARMACEUTICALS, INC. (US) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225851-A1 COMPOSITIONS AND METHODS USEFUL FOR TREATING DISEASES MCL1, BCL3, BCL9 SMN1; SMN2 1971/4885KMT2A 2058/4885MEN1 521/4885
US-20150216862-A1 2,2'-BIPHENAZINE COMPOUNDS AND METHODS USEFUL FOR TREATING DISEASES MCL1, BCL3, BCL2L1 SMN1; SMN2 1917/4885KMT2A 429/4885MEN1 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.